TIDMSTX
RNS Number : 4323C
Shield Therapeutics PLC
01 October 2018
Shield Therapeutics plc
("Shield" or the "Group")
Shield Therapeutics announces submission of a New Drug
Application (NDA) for Feraccru(R) for the treatment of iron
deficiency with the US Food and Drug Administration (FDA)
London, UK, 1(st) October 2018: Shield Therapeutics plc
(LSE:STX), a commercial stage, pharmaceutical company delivering
innovative specialty pharmaceuticals to address patients' unmet
medical needs, today announces that it has received confirmation
from the US FDA of its successful submission of an NDA for
Feraccru(R), Shield's lead product, which is already approved in
the European Union for the treatment of iron deficiency in adults
and in Switzerland for the treatment of iron deficiency anaemia in
adults with inflammatory bowel disease.
The United States, representing over a third of the global
pharmaceutical market, is a very attractive opportunity for
Feraccru(R) and a market which Shield retains full ownership of, as
well as complete control of the global intellectual property
rights.
Commenting on the announcement, Dr Jackie Mitchell, VP of
Regulatory Affairs and Quality at Shield Therapeutics, said: "This
NDA submission is a key regulatory milestone in widening Feraccru's
geographical availability for patients suffering from iron
deficiency and it builds on the significant broadening of the
product's indication from patients with anaemia and inflammatory
bowel disease (IBD) to the treatment of all adults with iron
deficiency (ID) with or without anaemia approved in the European
Union earlier this year."
Carl Sterritt, Chief Executive Officer of Shield Therapeutics,
added: "Filing of this NDA is a major step towards the potential
regulatory approval of Feraccru in the USA. I am delighted with the
rapid progress the team has made with this submission and would
also like to thank the clinicians and patients who took part in the
studies that have formed part of this NDA. Following on from the
recently announced licensing agreement with Norgine for the
commercialisation of Feraccru in Europe, we are very excited about
the future for Feraccru and the value creation opportunities that
lie ahead for Shield."
- Ends -
For further information please contact:
Shield Therapeutics plc +44 (0)207 186 8500
Carl Sterritt, Chief Executive Officer
Tim Watts, Interim Chief Financial Officer
Nominated Advisor and Joint Broker +44 (0)203 100 2222
Liberum Capital Limited
Christopher Britton/Steve Pearce
Joint Broker +44 (0)207 418 8900
Peel Hunt LLP
James Steel/ Dr Christopher Golden
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
About Feraccru(R)
Feraccru(R) is a novel, stable, non-salt, oral formulation of
ferric iron, which has a differentiated mechanism of action
compared to salt-based oral iron therapies. When salt-based oral
iron therapies are ingested, the iron must dissociate from the salt
in the GI tract to allow the iron to be absorbed and treat the IDA.
This free iron readily chelates to form insoluble clumps and
produces damaging free radicals that together cause a range of
mild-to-severe GI adverse events, including nausea, bloating and
constipation, leading to poor tolerability, reduced patient
compliance and ultimately treatment failure. In addition, many
patients with IDA are concurrently treated with medicines that
raise the pH in the gut which further reduces the effect of
salt-based oral iron therapies as they require highly acidic
conditions to be absorbed. Feraccru(R) is not an iron salt, and
iron can be absorbed from the ferric maltol molecule, and as a
result, it does not routinely cause the same treatment-limiting
intolerance issues. Feraccru(R) has been shown in clinical trials
to be well-tolerated by patients even when they had previously
failed treatment with salt-based oral iron therapies, which should
lead to increased patient compliance and better patient
outcomes.
Currently, the only treatment option for IDA patients who cannot
tolerate salt-based oral iron therapies, is IV iron therapy. IV
iron therapies quickly increase iron stores via direct
administration of very large doses of iron, causing an increase in
Hb levels that is physiologically controlled and occurs over a
period of weeks, as is the case with Feraccru(R). IV iron
therapies, however, are invasive, costly, inconvenient and complex
to administer, and also come with potentially life-threatening,
spontaneous hypersensitivity reactions.
Feraccru(R) has been approved by the European Commission for the
treatment of iron deficiency in adults, with or without
anaemia.
About Shield Therapeutics plc
Shield is a commercial stage, pharmaceutical company delivering
innovative specialty pharmaceuticals to address patients' unmet
medical needs. Our clear purpose is to help our patients become
people again, by enabling them to enjoy the things that make the
difference in their everyday lives. The Group has a marketed
product, Feraccru(R), for the treatment of iron deficiency in adult
patients with or without anaemia. Feraccru(R) has exclusive IP
rights until the mid-2030's. For more information please visit
www.shieldtherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements. These forward-looking statements are based on
management's current expectations and include statements related to
the timing of future results of Feraccru trials and the timing and
success of the Group's regulatory plans and commercial strategy for
Feraccru. These statements are neither promises nor guarantees, but
involve known and unknown risks and uncertainties, many of which
are beyond our control, that may cause actual results, performance
or achievements to be materially different from management's
expectations expressed or implied by the forward-looking
statements, including, but not limited to, risks associated with
the regulatory approval process, the Group's business and results
of operations, competition and other market factors. The
forward-looking statements made in this press release represent
management's expectations as of the date of this press release, and
except as required by law, the Group disclaims any obligation to
update any forward-looking statements contained in this release,
even if subsequent events cause our views to change.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBCGDCGXXBGIG
(END) Dow Jones Newswires
October 01, 2018 02:00 ET (06:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024